Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.

Gilead Sciences is expanding beyond its core HIV business with four potential drug launches in 2026, including treatments for hepatitis delta virus, multiple myeloma, and breast cancer. Despite strong financials (Q1 revenue up 4% YoY, EPS up 54.8%), the stock has only risen 9% this year. The company's strategic acquisitions and diversified pipeline, combined with no major patent cliffs until 2036 and an attractive 2.39% dividend yield, suggest investors are undervaluing the company's growth potential.